MRA Contrast Agent Enhances View of AIOD

 

January 20, 2010
Ablavar has an MRA indication to evaluate aortoiliac occlusive disease.

Ablavar is a contrast agent approved for use with a magnetic resonance angiography (MRA) indication to evaluate aortoiliac occlusive disease (AIOD) and suspected peripheral vascular disease.

It demonstrated statistically greater sensitivity (detecting disease when present) compared with noncontrast MRA. These studies, which supported the U.S. Food and Drug Administration (FDA) approval of Ablavar, show that MRA images using Ablavar provided diagnostic accuracy comparable to conventional X-ray angiography, an invasive procedure which involves insertion of a catheter into the arteries in the upper thigh (groin area) or arm.

Lantheus Medical Imaging's Ablavar's designed to provide distinct advantages over X-ray angiography, high resolution images comparable to conventional X-ray angiography to offer radiologists enhanced visualization of patients’ arteries. Ablavar is given in a single, low dose injection, and does not require catheter insertion into a patient’s arteries, and does not expose patients to ionizing radiation.

Contraindications: History of a prior allergic reaction to a gadolinium-based contrast agent. Gadolinium-based contrast agents increase the risk of nephrogenic systemic fibrosis (NSF) in patients with:
- acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period. In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with noncontrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle, and internal organs. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent from the body prior to any re-administration.

For more information: www.ablavar.com and www.lantheus.com

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.